| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.7M | -19.5% | -10.0% |
| SG&A Expense | $3.2M | -60.0% | +4.3% |
| Operating Income | -$7.9M | +42.9% | +4.7% |
| Net Income | -$5.5M | +54.5% | +33.1% |
| EPS (Basic) | -$0.23 | +55.8% | +34.3% |
| EPS (Diluted) | -$0.23 | +55.8% | +34.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $12.0M | — | — |
| Current Assets | $15.2M | — | — |
| Total Assets | $34.9M | — | — |
| Current Liabilities | $7.0M | — | — |
| Total Liabilities | $7.7M | — | — |
| Stockholders' Equity | $27.2M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$10.9M | — | — |
| Capital Expenditures | $770K | — | — |
| Investing Cash Flow | -$770K | — | — |
| Financing Cash Flow | $10.5M | — | — |
| Free Cash Flow | -$11.7M | — | — |
| -12.7% |